Valsartan
Valsartan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Takotsubo Cardiomyopathy。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
11 项
已进入 III/IV 期
11 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University of Edinburgh
- The Searle Company Limited Pakistan
- Shenzhen People's Hospital
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Chong Kun Dang Pharmaceutical
- Novartis Pharmaceuticals
- Hospital do Coracao
- Beijing Friendship Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Pakistan、中国、Russia、South Korea、美国、加拿大、Brazil、中国香港、挪威、Egypt、United Arab Emirates
正在招募患者的 Valsartan 研究
Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.
不适用招募中PakistanNCT06625346S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
III 期招募中中国NCT05553886Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
II 期招募中RussiaNCT06655480Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
III 期招募中South KoreaNCT06643819A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
I 期招募中美国加拿大NCT07465653Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
III 期招募中BrazilNCT06930885Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
不适用招募中中国NCT05498675Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
IV 期招募中South KoreaNCT07572032Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control
不适用招募中中国香港NCT07458880Bariatric Surgery and Pharmacokinetics of Valsartan
不适用招募中挪威NCT03535376Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
不适用招募中EgyptNCT07192341STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
IV 期招募中South KoreaNCT07631156A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
不适用招募中United Arab EmiratesNCT07465666Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial
I 期招募中PakistanNCT07444398NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
II 期招募中美国NCT04055428PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
II 期 / III 期招募中美国NCT04971720Effect of Sacubitril-Valsartan on Cardiac Structure and Function
III 期招募中美国NCT06693674A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
不适用招募中中国NCT07335900Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot
II 期 / III 期招募中加拿大NCT07539298Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
IV 期招募中美国NCT04191681Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
IV 期招募中中国NCT06917664Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
III 期招募中BrazilNCT05155137: Vascular Function in Health and Disease
I 期招募中美国NCT02966665Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
I 期 / II 期招募中美国NCT05194111
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。